Px HealthCare makes OWise, the regulated oncology platform that supports people through cancer treatment and that partners build evidence programmes on.
What patients record about their own treatment becomes structured, longitudinal, post-market approval evidence.
OWise sits in that gap. Patients record symptoms, side effects and wellbeing as they happen, on a regulated platform, under consent they control. That produces evidence which cannot be reconstructed from claims or hospital records after the fact.
Brand-agnostic education and support content, authored by Px, compliant with ABPI and equivalent codes. Px retains editorial control.
Built with partners around a named therapy or product, on the regulated platform patients already use, in the country-specific version for that market.
Structured, post-market approval real-world evidence, including symptom and tolerability data captured between appointments rather than at scheduled visits.
Two regulated apps, one platform. OWise is deployed in breast and prostate cancer, with the clinical content, symptom sets and decision tools built for each.
OWise breast cancer is a CE-marked Class I Medical Device, approved for NHS use, co-designed with breast cancer patients. It supports people through systemic treatment, where tolerability decides whether therapy continues, with a side effect and symptom set specific to breast cancer.
It runs in country-specific versions built on national clinical guidelines in the UK, the Netherlands and the US, and carries the majority of the platform’s longitudinal evidence base.
OWise prostate cancer is a CE-marked Class I Medical Device, approved for NHS use, co-designed with prostate cancer patients. It includes a shared decision making tool for choosing a first treatment, PSA tracking, and monitoring of the symptoms and side effects specific to prostate cancer and men’s health.
Currently available in the UK.
With OWise as the core platform, Px designed a UK nationwide real-world observational study, sponsored by a leading pharma company, to capture longitudinal patient-reported outcomes in routine NHS care. The study design was approved by the HRA and the REC, and was presented at the San Antonio Breast Cancer Symposium in 2023.
Established by medical scientists in 2012, Px is headquartered in London. OWise has been in use since 2013 and has been independently evaluated in peer-reviewed journals. Founder Dr Anne Bruinvels previously formed and exited a data-mining biotech company listed on the London Stock Exchange. Medical Director Dr David Bruinvels is an occupational physician specialising in oncology and a qualified epidemiologist.
Patients own their data and decide who sees it. Consent is dynamic and purpose-specific, so a patient can see what their data is being used for and withdraw at any point. That is not a compliance detail added later. It is how the company was built, and it is the reason the evidence generated on the platform can be used.
Structured, consented, longitudinal symptom data is the hardest input to obtain in oncology AI. We develop predictive models on it with partners rather than licensing it as training data.
